Antioxidant therapy and HIV infection: 1998

HIV - 1 Group O Infection in Cameroon , 1986 – 1998

Emerging Infectious Diseases Vol. 7, No. 3, May–June 2001 466 HIV-1 group O (HIV-1/O) was first identified in Cameroon in 1994 (1), raising concern about the emergence of a new HIV-1 variant, with implications for public health and blood safety. Anti-HIV-1/O antibodies are weakly detected by some HIV-1 screening tests (2), and the natural resistance of most HIV-1/O strains to nonnucleoside inhi...

HIV-1 group O infection in Cameroon, 1986 to 1998.

We report a survey of HIV-1 group O infection in Cameroon during 1986 to 1998. The prevalence of HIV-1/O decreased from 0.6% to 0.4%, while HIV-1/M increased from 19.2% to 31.5% from 1994 to 1998. We concluded that HIV-1/O infection is stable in Cameroon and may be declining slightly.

Antiretroviral Therapy for HIV Infection

The HIV/AIDS is now twenty five years old and, in these 25 years, more than 60 million people have been infected by human immunodeficiency virus (HIV). As on December 2006, nearly 39.5 million people globally are living with HIV/AIDS1. During this period, lot of efforts have gone into understanding the structure of viruses, its molecular biology and the pathogenesis of disease. The information ...

Complications of HIV infection and antiretroviral therapy.

HIV Infection, Antiretroviral Therapy and Cardiovascular Risk

In the last 15 years, highly active antiretroviral therapy (HAART) has determined a dramatic reduction of both morbidity and mortality in human immunodeficiency virus (HIV)-infected subjects, transforming this infection in a chronic and manageable disease. Patients surviving with HIV in the developed world, in larger number men, are becoming aged. As it would be expected for a population of com...